Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Louis de Mestier

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9715-9189; OpenAlex author ID A5009980652. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
109
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 4 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers · 2026: 3 papers

Papers 29

  1. Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectom… Co-author DOI 10.1007/s00464-026-12991-3↗
  2. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  3. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  4. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  5. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  6. Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and… Co-author DOI 10.1016/j.hpb.2025.04.009↗
  7. Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients. Last author DOI 10.1177/17588359251403909↗
  8. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  9. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  10. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  11. Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. Last author DOI 10.1177/17588359231163776↗
  12. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  13. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Co-author DOI 10.1177/17588359221118019↗
  14. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2021.05.006↗
  15. Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. Co-author DOI 10.1158/1078-0432.ccr-21-1907↗
  16. Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential dia… Co-author DOI 10.1177/17588359211053412↗
  17. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.dld.2020.03.014↗
  18. PARP inhibition in treatment of pancreatic cancer. Co-author DOI 10.1080/14737140.2020.1820330↗
  19. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Co-author DOI 10.1177/1758835920937949↗
  20. Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments. First author DOI 10.1177/2050640620939788↗
  21. Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. Co-author DOI 10.1111/cge.13629↗
  22. Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition o… Co-author DOI 10.1177/2050640618824910↗
  23. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Co-author DOI 10.3390/cancers11111808↗
  24. Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer. Last author DOI 10.3748/wjg.v25.i34.5082↗
  25. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  26. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
  27. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Co-author DOI 10.1530/erc-16-0269↗
  28. [Pancreatic adenocarcinoma: 10 years of progress]. Co-author DOI 10.1016/s0007-4551(15)31219-4↗
  29. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Co-author DOI 10.1111/his.12691↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 18 shared papers, 2015–2026 · strength 2.57
  2. Pascal R. Hammel · 18 shared papers, 2015–2026 · strength 2.04
  3. Vinciane Rebours · 13 shared papers, 2016–2026 · strength 1.85
  4. Rémy Nicolle · 10 shared papers, 2019–2026 · strength 1.60
  5. Jean‐Baptiste Bachet · 11 shared papers, 2015–2026 · strength 1.49
  6. Cindy Neuzillet · 12 shared papers, 2015–2025 · strength 1.32
  7. Nelson Dusetti · 6 shared papers, 2022–2026 · strength 1.03
  8. Safi Dokmak · 5 shared papers, 2019–2026 · strength 1.00
  9. Anthony Turpin · 6 shared papers, 2020–2026 · strength 0.96
  10. Alain Sauvanet · 5 shared papers, 2015–2026 · strength 0.92
  11. Magali Svrcek · 6 shared papers, 2019–2024 · strength 0.70
  12. Juan Iovanna · 4 shared papers, 2022–2025 · strength 0.67
  13. Olivier Bouché · 5 shared papers, 2017–2026 · strength 0.61
  14. Olivia Hentic · 4 shared papers, 2015–2025 · strength 0.59
  15. Pierre Laurent‐Puig · 4 shared papers, 2019–2026 · strength 0.57
  16. Mickaël Lesurtel · 2 shared papers, 2025–2026 · strength 0.56
  17. Anne Couvelard · 4 shared papers, 2015–2025 · strength 0.56
  18. Shulin Zhao · 3 shared papers, 2021–2026 · strength 0.49
  19. Maxime Ronot · 2 shared papers, 2025 · strength 0.47
  20. Julien Taı̈eb · 3 shared papers, 2018–2026 · strength 0.46
  21. Magali Richard · 3 shared papers, 2022–2025 · strength 0.46
  22. Isabelle Trouilloud · 2 shared papers, 2024–2026 · strength 0.40
  23. Anne‐Laure Védié · 2 shared papers, 2024–2025 · strength 0.38
  24. Alice Boilève · 2 shared papers, 2024–2025 · strength 0.38
  25. Baiyong Shen · 2 shared papers, 2024–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.